Krista Davis Sells 1,000 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the transaction, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at approximately $4,131,164.80. This trade represents a 1.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Krista Davis also recently made the following trade(s):

• On Wednesday, December 11th, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP traded down $2.37 on Monday, hitting $55.57. 549,654 shares of the company traded hands, compared to its average volume of 187,258. The business’s 50 day moving average price is $57.08 and its 200-day moving average price is $58.20. ANI Pharmaceuticals, Inc. has a 52-week low of $52.50 and a 52-week high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of -101.04 and a beta of 0.74.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. US Bancorp DE increased its holdings in ANI Pharmaceuticals by 842.9% in the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after acquiring an additional 531 shares in the last quarter. KBC Group NV boosted its position in shares of ANI Pharmaceuticals by 89.2% in the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after purchasing an additional 600 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of ANI Pharmaceuticals in the fourth quarter worth $166,000. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of ANI Pharmaceuticals by 24.2% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after purchasing an additional 579 shares during the period. Finally, Rafferty Asset Management LLC purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at $200,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ANIP has been the subject of a number of research analyst reports. Leerink Partnrs raised shares of ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. StockNews.com raised ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. HC Wainwright reissued a “buy” rating and issued a $94.00 target price on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Leerink Partners began coverage on ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price target for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.